Compare Recursion Pharmaceuticals Inc (RXRX) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wynn Resorts, Limited — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Wynn Resorts, Limited trades at $75.15 (market cap $7.75B). The key difference: Wynn Resorts, Limited is far larger — about 3.6× Recursion Pharmaceuticals Inc's market cap, and Wynn Resorts, Limited pays a 1.33% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Wynn Resorts, Limited for 76 Days on average.
| RXRX | WYNN | |
|---|---|---|
Market Cap | $2.14B | $7.75B |
Volume | 30,789,535 | 2,243,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $133.09 |
52-Week Low | $2.84 | $74.97 |
Typical Hold Time | 23 Days | 76 Days |
Enterprise Value | $1.66B | $17.99B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Wynn Resorts trades at $75.29, up 0.43% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported Q2 2026 EPS of $1.24, beating expectations, driven by Macau strength, but faces margin pressure in the U.S. and rising capital expenditure for new projects. Revenue for 2025 was $7.14 billion with a net income margin of 4.58%, while the balance sheet shows high long-term debt of $10.50 billion and negative shareholder equity.
The outlook is mixed: analyst consensus is bullish with a $132.36 price target, but risks include high leverage, project costs, and competitive pressures. Upside hinges on Macau recovery and successful project execution, while downside risks stem from debt servicing and macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
